daptomycin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease
Trial Timeline
Aug 12, 2007 → May 12, 2008
NCT ID
NCT00490737About daptomycin
daptomycin is a phase 1 stage product being developed by Merck for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00490737. Target conditions include End-Stage Renal Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01025271 | Pre-clinical | Terminated |
| NCT01019395 | Phase 1 | Completed |
| NCT01012089 | Pre-clinical | Completed |
| NCT00701636 | Phase 3 | Completed |
| NCT00679835 | Phase 1 | Completed |
| NCT00490737 | Phase 1 | Completed |
| NCT00467272 | Phase 2 | Completed |
| NCT00663403 | Approved | Completed |
| NCT00507247 | Phase 2 | Completed |
| NCT00136292 | Phase 1 | Completed |
| NCT00651131 | Approved | Terminated |
| NCT00055198 | Phase 3 | Terminated |
| NCT00093067 | Phase 3 | Completed |
| NCT00540072 | Phase 3 | Completed |
| NCT00538694 | Phase 3 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease